Abstract:Objective To evaluate effects of celecoxib (a selective cox-2 inhibitor)combined with fluvastatin (a HMG-CoA reductase inhibitor) on tumor growth and cell apoptosis in hepatocellular carcinoma xenograft in nude mice. Methods Hepatocellular carcinoma BEL-7402 cells were inoculated subcutaneously into the left armpit of nude mice, the mice (n = 32) were then randomly divided into 4 groups: the control group, the celecoxib group,the fluvastatin group and the combination group. At the end of the study,Tumor Tissues were collected for analysis. Cell apoptosis was determined by flow cytometry analysis and TUNEL assay. Akt, p-Akt and survivin protein levels were measured by Western blot. Statistical comparisons were made using factorial analysis of variance (ANOVA) and multiple comparisons between each two groups were calculated using SNK-q test. Results The combination of Celecoxib and fluvastatin resulted in a greater inhibition of tumor growth than either agent alone, the tumor inhibitory rate was 34.0% in the Celecoxib group, 25.0% in the fluvastatin group and 72.2% in the combination group. The percentages of TUNEL--positive cancer cells in the celecoxib and fluvastatin alone treatment groups were 8.5% ± 1.4% and 9.4% ±1.7% respectively as compared to the control group which was 3.5% ± 0.8%. Combination therapy showed a significantly greater increase in tumor cell apoptosis in comparison with the control and single-therapy groups (apoptotic index: 19.4% ± 3.0%; P ＜ 0.01 versus celecoxib or fluvastatin groups). The results of flow cytometry analysis also showed the same tendency. a small number of apoptotic cells were detected in the control tumours (4.1% ± 1.6%), whereas a large number of apoptotic cells were detected in tumours treated with celecoxib (9.1% ± 2.1%) or fluvastatin (10.1% ± 2.3%) alone; and the combination therapy resulted in even more apoptotic cells (23.6% ± 5.8%; P ＜ 0.01 versus celecoxib or fluvastatin groups). Western blot analysis demonstrated that the combination of celecoxib and fluvastatin significantly down-regulated p-Akt (0.23 ± 0.08 versus 1.12 ± 0.07 and surviving (0.50 ± 0.07 versus 1.47 ± 0.19) in BEL-7402 tumours compared with the control (P ＜ 0.01 for all). Conclusion The present study provided evidence that treatment with celecoxib in combination with fluvastatin resulted in the inhibition of HCC tumour growth in an in vivo mouse model. Key words: Carcinoma, hepatocellular; Mice, nude; Apoptosis; Celecoxib; Fluvastatin

Effect of Pirarubicin Combined with Celecoxib on Bladder Cancer Cell Line 5637

Effect of combined administration of hydroxycamptothecin and pirarubicin in human bladder cancer cell line 5637

Apoptosis Induced by Celecoxib Eombinated with Cisplatin in Human Osteosarcoma Cell Line MG-63 Via Down-Regulation of PI3K/Akt

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Apoptotic mechanism of pirarubicin against bladder cancer

Effect Of Celecoxib Combined With Chemotherapy Drug On Malignant Biological Behaviors Of Gastric Cancer

Effect of Celecoxib Combined with Thermotherapy on Cell Cycle of Pancreatic Carcinoma

Effect of Taxotere Combination with Celecoxib on Proliferation of NSCLC Cell

Parthenolide Augments the Anticancer Effects of 5-Fluorouracil on Cell Apoptosis and Decreased Nf-Kappa B Activity in A Gastric Cancer Cell Line

Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma

[Mechanism of Intravesical Instillation of Pirarubicin for Preventing Recurrence of Non-Muscle Invasive Bladder Cancer].

Capsaicin Enhances Anti-Proliferation Efficacy of Pirarubicin Via Activating TRPV1 and Inhibiting PCNA Nuclear Translocation in 5637 Cells.

Pirarubicin Inhibits Multidrug-Resistant Osteosarcoma Cell Proliferation Through Induction of G2/M Phase Cell Cycle Arrest

Anticancer Effects on Bladder Cancer Cell line T24 by Celecoxib

Study on the Mechanism of Celecoxib Inhibiting Growth and Inducing Apoptosis of Human Gastric Cancer Cell Line SGC-7901

Oxycodone enhances antitumor effect of paclitaxel on human breast cancer SKBR3 cells in vitro

β-Arbutin and cisplatin: A combined approach to modulating apoptosis, cell viability, and migration in bladder cancer cells

Effect of Hydroxycamptothecin Combined with Pirarubicin in the Treatment of Superficial Bladder Cancer Recurrence

Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3]

Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells

Promotion of Pirarubicin-Induced Apoptosis of Bladder Cancer Cells (BIU-87) Through Inhibiton of Autophagy by 3-Methyladenine